Top

07-03-2024 | Anaplastic Large Cell Lymphoma

Update on T-Cell Lymphoma Epidemiology

Authors: Jane J. Chen, Franco Castillo Tokumori, Christina Del Guzzo, Jeanyoung Kim, Jia Ruan

Published in: Current Hematologic Malignancy Reports

Abstract

Purpose of Review

T-cell lymphomas (TCLs) are a group of rare subtypes of non-Hodgkin lymphoma derived from mature T-lymphocytes. Recent updates in lymphoma classification based on the cell-of-origin pathogenesis have shed new light on TCL epidemiology and outcomes. Contemporary regional consortia and international studies, including those conducted recently in Asia and South America, have provided an updated delineation of the major subtypes across various global regions.

Recent Findings

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), remains the most common subtype globally except in Asia, where extra-nodal NK-T cell lymphoma (ENKTL) has emerged as the most prevalent. Angioimmunoblastic T-cell lymphoma (AITL) is the second most common subtype globally except in South America where its incidence falls behind adult T-cell leukemia/lymphoma (ATLL) and ENKTL. ALK-negative anaplastic large cell lymphoma (ALCL) has been recognized as the second most common subtype in some parts of South America. Studies on the newly classified breast implant-associated ALCL (BIA-ALCL) are beginning to reveal its distribution and risk factors.

Summary

Deciphering the epidemiology of TCLs is a challenging endeavor due to the rarity of these entities and ongoing refinement in classification. Collaborative efforts on prospective registries based on the most current WHO classifications will help capture the true epidemiology of TCL subtypes to better focus resources for diagnostic, prognostic, and therapeutic efforts.

•• Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBdO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–48. https://doi.org/10.1038/s41375-022-01620-2. Most recent update to the WHO classification of TCLs.

•• Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229–53. https://doi.org/10.1182/blood.2022015851. Most recent update to the ICC classification of TCLs.CrossRefPubMedPubMedCentral

Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin's Lymphoma. Med Sci (Basel). 2021;9(1). https://doi.org/10.3390/medsci9010005.

• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30. https://doi.org/10.1200/jco.2008.16.4558. Report from the ITCLP, the first global retrospective study of TCL epidemiology.CrossRefPubMed

• Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570–7. https://doi.org/10.1182/blood-2014-04-573089. Large population-based study of TCLs including epidemiology in Sweden.CrossRefPubMed

• Chiattone C, Civallero M, Fischer T, Miranda E, Manni M, Zing NPC, et al. Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: report from the prospective international T-cell lymphoma project. Hematol Oncol. 2022;40(5):953–61. https://doi.org/10.1002/hon.3074. Report from the T-Cell Lymphoma Project, the largest prospective global PTCL cohort study, with epidemiological data on ALK+ ALCL.CrossRefPubMed

• Federico M, Chiattone CS, Prince HM, Pavlovsky A, Manni M, Civallero M, et al. subtypes of mature T and NK cell lymphomas according to 2016 WHO classification. Preliminary report of the International Prospective T-Cell Project 2.0. Hematological Oncology. 2021;39(S2). https://doi.org/10.1002/hon.135_2880. Prelimary results from the prospective T-Cell Project 2.0 using the WHO 2016 classification.

•• Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, Koh Y, et al. Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. Lancet Reg Health West Pac. 2021;10:100126. https://doi.org/10.1016/j.lanwpc.2021.100126. Report from the first prospective registry study of NK/TCLs in Asia involving multiple countries.CrossRefPubMedPubMedCentral

• Fischer T, Idrobo H, Pavlovsky A, Castro D, Beltran B, Enriquez DJ, et al. Epidemiology, clinical features and outcomes of peripheral T-cell lymphoma in Latin America. Blood. 2023;142(Supplement 1):186-. https://doi.org/10.1182/blood-2023-187254. Report from the largest pooled cohort of PTCLs in Latin America.

10.

• Ruan J, Chen Z, Larson MC, Bennani NN, Wallace D, Allen PB, et al. Patterns of care and impact of initial treatment in peripheral T-cell lymphoma: outcome analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study. Blood. 2023;142(Supplement 1):3079-. https://doi.org/10.1182/blood-2023-180318. Report from the LEO-MER cohort, the largest prospective cohort study of PTCLs in the USA.

11.

Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States. J Clin Oncol. 2016;34(9):963–71. https://doi.org/10.1200/jco.2015.63.5540.CrossRefPubMedPubMedCentral

12.

• Foss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, et al. Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. Am J Hematol. 2020;95(2):151–5. https://doi.org/10.1002/ajh.25674. Report from the T-Cell Lymphoma Project with epidemiological data on HSTCL and EATL.CrossRefPubMed

13.

• Federico M, Bellei M, Pesce EA, Horwitz SM, Montoto S, Zucca E, et al. T-Cell Project: an international, prospective, observational study of patients with aggressive peripheral NK/T-cell lymphoma. Lesson from the First 1308 Patients. Hematological Oncology. 2015;33:100–80. Interim report from the prospective T-Cell project 1.0 that includes median age of patients.

14.

Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project Ann Oncol. 1998;9(7):717–20. https://doi.org/10.1023/a:1008265532487.CrossRefPubMed

15.

de Leval L, Jaffe ES. Lymphoma classification. Cancer J. 2020;26(3):176–85. https://doi.org/10.1097/ppo.0000000000000451.CrossRefPubMed

16.

Wang SS, Flowers CR, Kadin ME, Chang ET, Hughes AM, Ansell SM, et al. Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):66–75. https://doi.org/10.1093/jncimonographs/lgu012.CrossRefPubMedPubMedCentral

17.

•• Swerdlow SH, World Health O, International Agency for Research on C. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition ed. World Health Organization classification of tumours. Lyon: International Agency for Research on Cancer; 2017. Revised 4^th edition of the WHO classification of haematopoietic and lymphoid tissues.

18.

• Carson KR, Foss FM, Pinter-Brown L, Horwitz SM, Rosen ST, F, et al. Analysis Of Peripheral T-cell lymphoma (PTCL) subtype by race and geography using the Comprehensive Oncology Measures For Peripheral T-Cell Lymphoma Treatment (COMPLETE) dataset. Blood. 2013;122(21):4284-. https://doi.org/10.1182/blood.V122.21.4284.4284. Report from the COMPLETE study, an important prospective multicenter cohort of patients with new PTCL in the USA.

19.

• Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood. 2021;138(3):213–20. https://doi.org/10.1182/blood.2020010387. Report from the T-Cell Lymphoma Project with epidemiological data on AITL.CrossRefPubMedPubMedCentral

20.

Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25(11):2211–7. https://doi.org/10.1093/annonc/mdu443.CrossRefPubMedPubMedCentral

21.

Guru Murthy GS, Hamadani M, Bhatt VR, Dhakal I, Mehta P. Systemic anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: a population-based analysis of incidence and survival. Clin Lymphoma Myeloma Leuk. 2017;17(4):201–6. https://doi.org/10.1016/j.clml.2017.02.003.CrossRefPubMed

22.

Clarke CA, Morton LM, Lynch C, Pfeiffer RM, Hall EC, Gibson TM, et al. Risk of lymphoma subtypes after solid organ transplantation in the United States. Br J Cancer. 2013;109(1):280–8. https://doi.org/10.1038/bjc.2013.294.CrossRefPubMedPubMedCentral

23.

• Swerdlow SH, Cancer IAfRo, Organization WH. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer; 2008. 4^th edition of the WHO classification of haematopoietic and lymphoid tissues.

24.

• Shustov A, Cabrera ME, Civallero M, Bellei M, Ko YH, Manni M, et al. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. Blood Adv. 2021;5(3):640–8. https://doi.org/10.1182/bloodadvances.2020001581. Report from the T-Cell Lymphoma Project with epidemiological data on ALK- ALCL.CrossRefPubMedPubMedCentral

25.

• de Jong D, Vasmel WL, de Boer JP, Verhave G, Barbé E, Casparie MK, van Leeuwen FE. Anaplastic large-cell lymphoma in women with breast implants. Jama. 2008;300(17):2030–5. https://doi.org/10.1001/jama.2008.585. First epidemiological study identifying the association between breast implants and ALCL.

26.

Brody GS, Deapen D, Taylor CR, Pinter-Brown L, House-Lightner SR, Andersen JS, et al. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015;135(3):695–705. https://doi.org/10.1097/prs.0000000000001033.CrossRefPubMed

27.

Doren EL, Miranda RN, Selber JC, Garvey PB, Liu J, Medeiros LJ, et al. U.S Epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2017;139(5):1042–50. https://doi.org/10.1097/prs.0000000000003282.CrossRefPubMed

28.

Magnusson M, Beath K, Cooter R, Locke M, Prince HM, Elder E, Deva AK. The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants. Plast Reconstr Surg. 2019;143(5):1285–92. https://doi.org/10.1097/prs.0000000000005500.CrossRefPubMed

29.

Kinslow CJ, Kim A, Sanchez GI, Cheng SK, Kachnic LA, Neugut AI, Horowitz DP. Incidence of anaplastic large-cell lymphoma of the breast in the US, 2000 to 2018. JAMA Oncol. 2022;8(9):1354–6. https://doi.org/10.1001/jamaoncol.2022.2624.CrossRefPubMedPubMedCentral

30.

Stark B, Magnéli M, van Heijningen I, Parreira C, Bösch U, Rouif M, Halle M. Considerations on the demography of BIA-ALCL in European countries based on an E(A)SAPS survey. Aesthetic Plast Surg. 2021;45(6):2639–44. https://doi.org/10.1007/s00266-021-02411-3.CrossRefPubMedPubMedCentral

31.

Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113(17):3931–7. https://doi.org/10.1182/blood-2008-10-185256.CrossRefPubMed

32.

• Fox CP, Civallero M, Ko YH, Manni M, Skrypets T, Pileri S, et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematol. 2020;7(4):e284–94. https://doi.org/10.1016/s2352-3026(19)30283-2. Report from the T-Cell Lymphoma Project with epidemiological data on ENKTL.CrossRefPubMed

33.

Laurini JA, Perry AM, Boilesen E, Diebold J, Maclennan KA, Müller-Hermelink HK, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood. 2012;120(24):4795–801. https://doi.org/10.1182/blood-2012-07-440073.CrossRefPubMed

34.

Perry AM, Molina-Kirsch H, Nathwani BN, Diebold J, Maclennan KA, Müller-Hermelink HK, et al. Classification of non-Hodgkin lymphomas in Guatemala according to the World Health Organization system. Leuk Lymphoma. 2011;52(9):1681–8. https://doi.org/10.3109/10428194.2011.584254.CrossRefPubMed

35.

Lin GW, Xu C, Chen K, Huang HQ, Chen J, Song B, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2020;21(2):306–16. https://doi.org/10.1016/s1470-2045(19)30799-5.CrossRefPubMed

36.

Xu JX, Hoshida Y, Yang WI, Inohara H, Kubo T, Kim GE, et al. Life-style and environmental factors in the development of nasal NK/T-cell lymphoma: a case-control study in East Asia. Int J Cancer. 2007;120(2):406–10. https://doi.org/10.1002/ijc.22313.CrossRefPubMed

37.

Yi JH, Lee GW, Do YR, Jung HR, Hong JY, Yoon DH, et al. Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma. Ann Hematol. 2019;98(11):2541–50. https://doi.org/10.1007/s00277-019-03791-y.CrossRefPubMed

38.

de Leval L, Feldman AL, Pileri S, Nakamura S, Gaulard P. Extranodal T- and NK-cell lymphomas. Virchows Arch. 2023;482(1):245–64. https://doi.org/10.1007/s00428-022-03434-0.CrossRefPubMed

39.

Delabie J, Holte H, Vose JM, Ullrich F, Jaffe ES, Savage KJ, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood. 2011;118(1):148–55. https://doi.org/10.1182/blood-2011-02-335216.CrossRefPubMed

40.

Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790–5. https://doi.org/10.1002/ajh.24086.CrossRefPubMed

41.

Lebwohl B, Granath F, Ekbom A, Smedby KE, Murray JA, Neugut AI, et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann Intern Med. 2013;159(3):169–75. https://doi.org/10.7326/0003-4819-159-3-201308060-00006.CrossRefPubMedPubMedCentral

42.

Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029–38. https://doi.org/10.1182/blood-2007-10-119974.CrossRefPubMedPubMedCentral

43.

Howell WM, Leung ST, Jones DB, Nakshabendi I, Hall MA, Lanchbury JS, et al. HLA-DRB, -DQA, and -DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Common features and additional risk factors for malignancy. Hum Immunol. 1995;43(1):29–37. https://doi.org/10.1016/0198-8859(94)00130-i.CrossRefPubMed

44.

Deleeuw RJ, Zettl A, Klinker E, Haralambieva E, Trottier M, Chari R, et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology. 2007;132(5):1902–11. https://doi.org/10.1053/j.gastro.2007.03.036.CrossRefPubMed

45.

Yabe M, Miranda RN, Medeiros LJ. Hepatosplenic T-cell lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. Hum Pathol. 2018;74:5–16. https://doi.org/10.1016/j.humpath.2018.01.005.CrossRefPubMed

46.

Durani U, Go RS. Incidence, clinical findings, and survival of hepatosplenic T-cell lymphoma in the United States. Am J Hematol. 2017;92(6):E99-e101. https://doi.org/10.1002/ajh.24711.CrossRefPubMed

47.

Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28(15):2313–8. https://doi.org/10.1097/qad.0000000000000428.CrossRefPubMed

48.

Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36-41.e1. https://doi.org/10.1016/j.cgh.2010.09.016.CrossRefPubMed

49.

Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24(39):6058–68. https://doi.org/10.1038/sj.onc.1208968.CrossRefPubMed

50.

Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Frontiers in Microbiology. 2012;3. https://doi.org/10.3389/fmicb.2012.00322.

51.

Iwanaga M. Epidemiology of HTLV-1 Infection and ATL in Japan: an update. Front Microbiol. 2020;11:1124. https://doi.org/10.3389/fmicb.2020.01124.CrossRefPubMedPubMedCentral

52.

Ramassamy J-L, Tortevoye P, Ntab B, Seve B, Carles G, Gaquière D, et al. Adult T-cell leukemia/lymphoma incidence rate in French Guiana: a prospective cohort of women infected with HTLV-1. Blood Adv. 2020;4(9):2044–8. https://doi.org/10.1182/bloodadvances.2020001628.CrossRefPubMedPubMedCentral

53.

Malpica L, Enriquez DJ, Castro DA, Peña C, Idrobo H, Fiad L, et al. Real-world data on adult T-cell leukemia/lymphoma in Latin America: a study from the Grupo de Estudio Latinoamericano de Linfoproliferativos. JCO Glob Oncol. 2021;7:1151–66. https://doi.org/10.1200/go.21.00084.CrossRefPubMed

54.

Yoshida N, Chihara D. Incidence of adult T-cell leukemia/lymphoma in nonendemic areas. Curr Treat Options Oncol. 2015;16(2):7. https://doi.org/10.1007/s11864-014-0321-5.CrossRefPubMed

55.

Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primers. 2021;7(1):61. https://doi.org/10.1038/s41572-021-00296-9.CrossRefPubMed

56.

Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019;181(2):350–7. https://doi.org/10.1111/bjd.17258.CrossRefPubMed

57.

Virmani P, Levin L, Myskowski PL, Flores E, Marchetti MA, Lucas AS, et al. Clinical outcome and prognosis of young patients with mycosis fungoides. Pediatr Dermatol. 2017;34(5):547–53. https://doi.org/10.1111/pde.13226.CrossRefPubMedPubMedCentral

58.

Desai M, Liu S, Parker S. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort. J Am Acad Dermatol. 2015;72(2):276–85. https://doi.org/10.1016/j.jaad.2014.10.019.CrossRefPubMed

59.

Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas—an update 2021. Hematol Oncol. 2021;39(S1):46–51. https://doi.org/10.1002/hon.2850.CrossRefPubMed

60.

Mourad A, Gniadecki R. Overall survival in mycosis fungoides: a systematic review and meta-analysis. J Invest Dermatol. 2020;140(2):495-7.e5. https://doi.org/10.1016/j.jid.2019.07.712.CrossRefPubMed

61.

Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051–60. https://doi.org/10.1158/1078-0432.Ccr-12-0604.CrossRefPubMed

62.

• Dobos G, Pohrt A, Ram-Wolff C, Lebbé C, Bouaziz JD, Battistella M, et al. Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients. Cancers (Basel). 2020;12(10). https://doi.org/10.3390/cancers12102921. Recent large global epidemiological study of CTCLs.

63.

Su C, Nguyen KA, Bai HX, Cao Y, Tao Y, Xiao R, et al. Racial disparity in mycosis fungoides: an analysis of 4495 cases from the US National Cancer Database. J Am Acad Dermatol. 2017;77(3):497-502.e2. https://doi.org/10.1016/j.jaad.2017.04.1137.CrossRefPubMed

64.

Aschebrook-Kilfoy B, Cocco P, La Vecchia C, Chang ET, Vajdic CM, Kadin ME, et al. Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sézary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):98–105. https://doi.org/10.1093/jncimonographs/lgu008.CrossRefPubMedPubMedCentral

65.

Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–22. https://doi.org/10.1182/blood-2007-03-055749.CrossRefPubMed

66.

Hapgood G, Pickles T, Sehn LH, Villa D, Klasa R, Scott DW, et al. Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. Br J Haematol. 2017;176(2):234–40. https://doi.org/10.1111/bjh.14404.CrossRefPubMed

67.

Sarfraz H, Gentille C, Ensor J, Wang L, Wong S, Ketcham MS, et al. Primary cutaneous anaplastic large-cell lymphoma: a review of the SEER database from 2005 to 2016. Clin Exp Dermatol. 2021;46(8):1420–6. https://doi.org/10.1111/ced.14777.CrossRefPubMed

68.

Melchers RC, Willemze R, Bekkenk MW, de Haas ERM, Horvath B, van Rossum MM, et al. Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis. J Eur Acad Dermatol Venereol. 2020;34(2):260–6. https://doi.org/10.1111/jdv.16065.CrossRefPubMed

69.

Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, Jaffe ES. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–14. https://doi.org/10.1182/blood-2018-11-881268.CrossRefPubMedPubMedCentral

70.

• Lee YP, Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, et al. Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. Int J Hematol. 2021;114(3):355–62. https://doi.org/10.1007/s12185-021-03179-7. Report from the first prospective study on NK/TCLs in Asia focusing on CTCLs with information about their epidemiology.CrossRefPubMed

Title: Update on T-Cell Lymphoma Epidemiology
Authors: Jane J. Chen
Franco Castillo Tokumori
Christina Del Guzzo
Jeanyoung Kim
Jia Ruan
Publication date: 07-03-2024
Publisher: Springer US
Keywords: Anaplastic Large Cell Lymphoma
Anaplastic Large Cell Lymphoma
Lymphoma
Primary Cutaneous Anaplastic Large Cell Lymphoma
Mycosis Fungoides
Published in: Current Hematologic Malignancy Reports
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-024-00727-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com